Our work shows that IFN is associated with suppressed GILZ in multiple conditions, including in vitro studies of human PBMC, as well as in vivo in SLE patients, in patients with MS taking therapeutic IFN, and in IFN-overexpressing mice. The gene discussed is IFNA1; the disease is myeloid sarcoma.